Cargando…
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Autores principales: | Knox, Tessa, Sahakian, Eva, Banik, Debarati, Hadley, Melissa, Palmer, Erica, Noonepalle, Satish, Kim, Jennifer, Powers, John, Gracia-Hernandez, Maria, Oliveira, Vasco, Cheng, Fengdong, Chen, Jie, Barinka, Cyril, Pinilla-Ibarz, Javier, Lee, Norman H., Kozikowski, Alan, Villagra, Alejandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785545/ https://www.ncbi.nlm.nih.gov/pubmed/31597938 http://dx.doi.org/10.1038/s41598-019-51403-6 |
Ejemplares similares
-
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
por: Knox, Tessa, et al.
Publicado: (2019) -
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model
por: Maharaj, Kamira, et al.
Publicado: (2020) -
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
por: Banik, Debarati, et al.
Publicado: (2019) -
Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019) -
Editorial: Genetic and Epigenetic Control of Immune Responses
por: Noonepalle, Satish kumar R., et al.
Publicado: (2021)